EXICURE, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
EXICURE, INC. (XCUR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $57.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $57.00K, a 21.28% increase year-over-year.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $129.00K, a 37.07% decline year-over-year.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was -$15.00K, a 107.46% decline year-over-year.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $218.00K, a 72.61% decline from fiscal 2024.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $796.00K, a 7.42% increase from fiscal 2023.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $741.00K, a 6.93% increase from fiscal 2022.
- EXICURE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $693.00K, a 5.64% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $57.00K 10-Q · filed 2026-08-14 | $186.00K derived: sum of 3 quarters · filed 2026-08-14 | $171.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $57.00K 10-Q · filed 2026-05-29 | $186.00K derived: sum of 2 quarters · filed 2026-05-29 | $171.00K derived: sum of 3 quarters · filed 2026-05-29 | $228.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $114.00K derived: sum of 2 quarters · filed 2026-03-25 | $171.00K derived: sum of 3 quarters · filed 2026-08-14 | $218.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $42.00K derived: sum of 2 quarters · filed 2026-08-14 | $89.00K 10-Q · filed 2025-11-07 | $294.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $104.00K 10-Q · filed 2026-08-14 | $309.00K derived: sum of 3 quarters · filed 2026-08-14 | $510.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $47.00K 10-Q · filed 2026-05-29 | $252.00K derived: sum of 2 quarters · filed 2026-05-29 | $453.00K derived: sum of 3 quarters · filed 2026-05-29 | $649.00K derived: sum of 4 quarters · filed 2026-05-29 |
| 2024-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $406.00K derived: sum of 2 quarters · filed 2026-03-25 | $602.00K derived: sum of 3 quarters · filed 2026-03-25 | $796.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $397.00K derived: sum of 2 quarters · filed 2025-11-07 | $591.00K 10-Q · filed 2025-11-07 | $781.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $196.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $390.00K 10-Q · filed 2025-08-08 | $580.00K derived: sum of 3 quarters · filed 2025-08-08 | $767.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $194.00K 10-Q · filed 2025-06-27 | $384.00K derived: sum of 2 quarters · filed 2025-06-27 | $571.00K derived: sum of 3 quarters · filed 2025-06-27 | $755.00K derived: sum of 4 quarters · filed 2025-06-27 |
| 2023-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $377.00K derived: sum of 2 quarters · filed 2025-03-18 | $561.00K derived: sum of 3 quarters · filed 2025-03-18 | $741.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $371.00K derived: sum of 2 quarters · filed 2024-11-14 | $551.00K 10-Q · filed 2024-11-14 | $728.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $364.00K 10-Q · filed 2024-08-13 | $541.00K derived: sum of 3 quarters · filed 2024-08-13 | $716.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $180.00K 10-Q · filed 2024-06-17 | $357.00K derived: sum of 2 quarters · filed 2024-06-17 | $532.00K derived: sum of 3 quarters · filed 2024-06-17 | $704.00K derived: sum of 4 quarters · filed 2024-06-17 |
| 2022-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $352.00K derived: sum of 2 quarters · filed 2024-06-06 | $524.00K derived: sum of 3 quarters · filed 2024-06-06 | $693.00K 10-K · filed 2024-06-06 |
| 2022-09-30 | $175.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-05-16 | $347.00K derived: sum of 2 quarters · filed 2024-06-06 | $516.00K 10-Q · filed 2024-05-16 | $683.00K derived: sum of 4 quarters · filed 2024-06-06 |
| 2022-06-30 | $172.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-06-06 | $341.00K 10-Q/A · filed 2024-06-06 | $508.00K derived: sum of 3 quarters · filed 2024-06-06 | $672.00K derived: sum of 4 quarters · filed 2024-06-06 |
| 2022-03-31 | $169.00K 10-Q/A · filed 2024-06-06 | $336.00K derived: sum of 2 quarters · filed 2024-06-06 | $500.00K derived: sum of 3 quarters · filed 2024-06-06 | $663.00K derived: sum of 4 quarters · filed 2024-06-06 |
| 2021-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $331.00K derived: sum of 2 quarters · filed 2023-03-27 | $494.00K derived: sum of 3 quarters · filed 2023-03-27 | $656.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $327.00K derived: sum of 2 quarters · filed 2022-11-14 | $489.00K 10-Q · filed 2022-11-14 | $652.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $325.00K 10-Q · filed 2022-08-15 | $488.00K derived: sum of 3 quarters · filed 2022-08-15 | $650.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $162.00K 10-Q · filed 2022-05-16 | $325.00K derived: sum of 2 quarters · filed 2022-05-16 | $487.00K derived: sum of 3 quarters · filed 2022-05-16 | $698.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $325.00K derived: sum of 2 quarters · filed 2022-03-25 | $536.00K derived: sum of 3 quarters · filed 2022-03-25 | $681.00K 10-K · filed 2022-03-25 |
| 2020-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-19 | $373.00K derived: sum of 2 quarters · filed 2021-11-19 | $518.00K 10-Q · filed 2021-11-19 | $540.00K derived: sum of 4 quarters · filed 2021-11-19 |
| 2020-06-30 | $211.00K 10-Q · filed 2020-08-12 | $356.00K 10-Q · filed 2021-08-12 | $378.00K derived: sum of 3 quarters · filed 2021-05-12 | |
| 2020-03-31 | $84.00K 10-Q · filed 2021-05-12 | $167.00K derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $332.00K 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $249.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |